FIELD: organic chemistry; pharmaceuticals.
SUBSTANCE: group of inventions relates to compounds with inhibitory activity against monoacylglycerin acyl transferase 2 (MGAT2). A compound represented by formula (I) is disclosed, wherein R1 is hydrogen; R2a and R2b together with the adjacent carbon atom form ring B; ring B is represented by the formula: where each R6 is independently halogen, C1-C4 alkyloxy optionally substituted with substituent(s) selected from the group consisting of halogen, C1-C4 alkyloxy and phenyl, and n is 1 or 2; R3a is hydrogen; R3b is hydrogen; R4a is a group represented by the formula: where L3 is a single bond or C1-C4 alkylene optionally substituted with halogen, R7 is halogen, sulfamoyl optionally substituted with C1-C4 alkyl, C1-C4 alkyloxy optionally substituted with halogen, C1-C4 alkylsulfonyl, aromatic heterocyclyl which is 5-membered monocyclic group containing two heteroatoms selected from O and N, a non-aromatic heterocyclyl which is a 4-membered monocyclic group containing one heteroatom selected from S and optionally substituted with oxo, or a group represented by the formula: -S(= O)(=NRN)-RS1, RN is hydrogen and RS1 is C1-C4 alkyl; and R4b is C1-C6 alkyl optionally substituted with substituent group α, phenyl optionally substituted with substituent group β, or pyridyl optionally substituted with substituent β, substituent group α is halogen and cyclopropanyl, and substituent group β is halogen, cyano, C1-C4 alkyl, haloC1-C4 alkyl, hydroxyalkyl, C1-C4 alkyloxy, haloC1-C4 alkyloxy, cyclopropanyl, cyclopropanyloxy, C1-C4 alkylsulfonyl, or a pharmaceutically acceptable salt thereof. In addition, specific compounds are disclosed, a pharmaceutical composition having MGAT2 inhibitory activity containing the above compound or a pharmaceutically acceptable salt thereof, and a method of treating or preventing an MGAT2-associated disease, comprising administering the above compound.
EFFECT: group of inventions provides effective treatment of MGAT2-associated disease.
18 cl, 24 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2683245C1 |
BENZIMIDAZOLE OR IMIDAZOPYRIDINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH ACC2 | 2016 |
|
RU2702637C2 |
BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | 2017 |
|
RU2753524C2 |
METHOD FOR PREPARING SUBSTITUTED PYRAZOLES | 2002 |
|
RU2277534C2 |
NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITION ACTIVITY | 2016 |
|
RU2720145C2 |
HETEROCYCLIC DERIVATIVE HAVING ACTIVATING AMPK ACTIVITY | 2015 |
|
RU2700703C2 |
IMIDZOL DERIVATIVE CONDENSED HETEROCYCLE HAVING ACTIVE AMPK EFFECT | 2011 |
|
RU2635662C2 |
CONDENSED CYCLIC DERIVATIVE WITH INHIBITORY ACTIVITY AGAINST MGAT-2 | 2018 |
|
RU2770437C2 |
NUCLEIC ACID DERIVATIVE EXHIBITING IMMUNOSTIMULATING ACTIVITY | 2016 |
|
RU2730871C1 |
DRUG FOR INFLUENZA TREATMENT, CHARACTERIZED BY THE FACT THAT IT COMBINES A PER-DEPENDENT ENDONUCLEASE INHIBITOR AND A DRUG AGAINST FLU | 2016 |
|
RU2745071C2 |
Authors
Dates
2023-09-19—Published
2020-01-10—Filed